Summary
Objectives Healthcare workers (HCWs) are at high risk of latent tuberculosis infection (LTBI) due to their continued occupational exposure. The incidence of LTBI among the HCWs has seldom been investigated. Primary health centres (PHCs) provide effective and affordable medical care largely for the local population. The HCWs of PHCs who are likely to have increased occupational exposure have an increased risk of reactive as well as LTBI, and contribute to overall TB transmission than the general population.
Methods A cross-sectional study (March–April 2024) was carried out to assess the burden of LTBI among the HCWs of PHCs (n=64) across Chennai, India. Blood samples were analyzed for gamma interferon using a QuantiFERON-TB Gold Plus assay. A complete baseline health profile, including complete blood count, blood glucose, liver and renal functions, and ferritin levels was estimated to identify potential biomarkers that are independently associated with LTBI.
Results The present study revealed an LTBI prevalence of 25.3% (n=99) among PHC workers. The red cell distribution width was significantly associated with LTBI positivity among different biochemical and haematological parameters analyzed. Factors such as individuals’ age, underlying comorbid conditions (30.3%; n=30), and longer employment duration (28%; n=28) were significantly associated with IGRA positivity. IGRA positivity was significantly associated with decreased RDW-SD in females, overweight, and participants with ‘O’ blood group.
Conclusions The study reported a high prevalence of LTBI among HCWs of PHCs, which necessitates their periodical screening for the elimination of TB.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Health Mission, Tamil Nadu (680/NGS/NHMTNMSC/ENGG/2021) for the Directorate of Public Health and Preventive Medicine, WGS facility. M.L. is supported by grants through AI52731, the Swedish Research Council, the Swedish, Physicians against AIDS Research Foundation, the Swedish International Development Cooperation Agency, SIDASARC, VINNMER for Vinnova, Linkoping University Hospital Research Fund, CALF, and the Swedish Society of Medicine. V.V. is supported by the Office of Research Infrastructure Programs (ORIP/NIH) base grant P51 OD011132 to ENPRC A.M. is supported by Grant No. 12020/04/2018‐HR, Department of Health Research, Government of India. The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The authors thank the Indian SARS CoV‐2 Genomics Consortium (INSACOG), Department of Biotechnology, Ministry of Science and Technology, Government of India for their approval and inclusion of the State Public Health Laboratory (SPHL) as INSAGOG Genomic Sequencing Laboratory (IGSL) vide File No: RAD‐22017/28/2020‐KGDDBT‐Part (6) Dated 29th December 2021.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Ethical Committee of the Directorate of Public Health and Preventive Medicine, gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
